RxDoctor Payments Data

Neal Lippman, MD

Clinical Cardiac Electrophysiology · Hartford, CTNPI 1487698866

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $54,735 of the $68,547 with a category attached, or 79.9%. Abbott accounts for 72.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $28,141 and has fallen 94.2% since, to $1,646 in 2025.

$68,547in general payments, 2019–2025

Across 267 payments — averaging $256.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$50K
  • Medtronic$16K
  • Stereotaxis Inc$836
  • Boston Scientific$434
  • Atricure, Inc.$314
  • Davol Inc.$270
  • plus $737 from 13 others

What the payments were for

  • Consulting fees$54,73580%
  • Travel & lodging$6,2099%
  • Food & beverage$7,43611%
  • Entertainment$1660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,547 in reported general payments places this provider in the 80th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.

See all clinical cardiac electrophysiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$200,703
Medicare patients
668
Services billed
3,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$59,120
MultaqDronedarone Hcl33$45,618
XareltoRivaroxaban11$18,605
Dofetilide34$8,073
Mexiletine Hcl39$7,114
Flecainide Acetate58$2,793
Amiodarone Hcl49$710
Metoprolol Succinate45$629
ClopidogrelClopidogrel Bisulfate20$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$59,12057 claims
Sanofi-aventis U.S. LLCMultaq$59$45,61833 claims
Johnson & JohnsonXarelto$73$18,60511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.

Other clinical cardiac electrophysiology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →